With Aspen circling, Sigma gets piecemeal bids

Australia's Sigma Pharmaceuticals (SIP.AX) has received three bids for its Herron drugs arm and three bids for its Orphan Australia drugs business, as it seeks an improved bid for the entire company from South Africa's Aspen Pharmacare (APNJ.J). Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.